thymalfasin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-15. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Also operating under UPMC Presbyterian Shadyside is the UPMC Rooney Sports Complex, located less than 2 miles (3.2 km) from the Oakland-based facilities on Pittsburgh's South Side. The facilities combine to include over 1,600 beds, making it the fourth-largest hospital in the United States.
Isotopes are commonly used to determine the concentration of various elements or substances using the isotope dilution method, whereby known amounts of isotopically substituted compounds are mixed with the samples and the isotopic signatures of the resulting mixtures are determined with mass spectrometry.
Pakistan Horticulture Development and Export Company (PHDEC; Urdu: پاکستان باغبانی ترقی و برآمد کمپنی ) is a department of Ministry of Commerce of Pakistan. PHDEC was created due to the enormous potential of Pakistan's horticulture products in the global market. In the absence of a single ministry or institution responsible for development at all levels of the horticulture value chain it was considered important to set up PHDEC to uplift this sector, especially in light of the impact of globalization and World Trade Organization (WTO) regime. Pakistan Horticulture Development & Export Board (PHDEC), an autonomous body under the administrative control of Ministry of Commerce has been mandated with the development of horticulture industry of Pakistan with focus on exports. Its functions, inter alia, include provision of improved marketing infrastructure like establishment of agro processing zones, cold chain system, processing plants (for value added products). In 2019, Pakistan had targeted Philippines and China to further boost kinnow exports to these two countries. The implementation arrangements are preferably under the public private partnership (PPP) modality with a clear exit strategy. PHDEC envisions the vitalization of a dynamic and market driven horticulture sector, which is resilient, sustainable and responsive to meet the challenges of globalization.
==== Ethyl alcohol absorption ==== Relatively new research involves the encapsulation of digestive enzymes within a non-toxic polymer shell. The enzyme filled nanoshell has been proven in lab mice to absorb ethyl alcohol from the bloodstream, therefore resulting in reduced blood alcohol levels. It has been concluded that the particles act as organelles, which proposes other benefits to enzyme therapies. This discovery is introducing other studies, such as encapsulation methods for hair loss.
Sources: en.wikipedia.org
== Osteopathies, chondropathies, and acquired musculoskeletal deformities (730–739) == 730 Osteomyelitis, periostitis, and other infections involving bone 731 Osteitis deformans and osteopathies associated with other disorders 732 Osteochondropathies 732.7 Osteochondritis dissecans 733 Other disorders of bone and cartilage 733.0 Osteoporosis 733.1 Pathologic fracture 733.2 Cyst of bone 733.3 Hyperostosis of skull 733.4 Aseptic necrosis of bone 733.5 Osteitis condensans 733.6 Tietze's disease Costochondritis 733.7 Algoneurodystrophy 733.8 Malunion and nonunion of fracture 733.9 Other and unspecified disorders of bone and cartilage 733.90 Disorder of bone and cartilage, unspecified Osteopenia Ostealgia 733.92 Chondromalacia 734 Flat foot 735 Acquired deformities of toe 735.0 Hallux valgus 735.2 Hallux rigidus 735.4 Hammer toe, other 736 Other acquired deformities of limbs 736.1 Mallet finger 736.2 Other acquired deformities of finger 736.7 Other acquired deformities of ankle and foot 736.8 Acquired deformities of other parts of limbs 736.81 Unequal leg length (acquired) 736.89 Other acquired deformity of other parts of limb Winged scapula 736.9 Acquired deformity, limb, unspec. 737 Curvature of spine 737.1 Kyphosis (acquired) 737.2 Lordosis (acquired) 737.3 Scoliosis 737.9 Kyphosis/scoliosis, unspec.
Viral hemorrhagic fevers (VHFs) are a diverse group of infectious diseases characterized by fever and systemic damage to the circulatory system caused by RNA viruses. Viral hemorrhagic fevers cause symptoms ranging from mild to life-threatening, depending on the virus involved, but generally cause internal bleeding that leads to sudden onset of muscle pain, fever, and hypotension. In severe cases, it can cause life-threatening shock and bleeding from internal organs. While some VHFs are generally mild, such as nephropathia epidemica (caused by two species of hantavirus), many are debilitating or lethal without treatment. Outbreaks of VHFs tend to have high case fatality rates and disproportionately affect communities with poor health infrastructure. Therefore, the emergence of VHFs is a growing public health concern. VHFs are often zoonoses, meaning they can be transmitted from wild animals to human populations; for instance, the Lassa arenavirus is spread by mice. Viral hemorrhagic fevers are caused by members of seven families of single-stranded RNA viruses: Arenaviridae, Filoviridae, Flaviviridae, Nairoviridae, Phenuiviridae, Hantaviridae and Peribunyaviridae.
LC-MS is particularly amenable to detecting hydrophobic molecules (lipids, fatty acids) and peptides while GC-MS is best for detecting small molecules (<500 Da) and highly volatile compounds (esters, amines, ketones, alkanes, thiols). Unlike the genome or even the proteome, the metabolome is a highly dynamic entity that can change dramatically, over a period of just seconds or minutes. As a result, there is growing interest in measuring metabolites over multiple time periods or over short time intervals using modified versions of NMR or MS-based metabolomics.
=== Scope and related laser-based procedures === LANAP is commonly described as a wavelength-dependent, flapless periodontal pocket treatment protocol performed with an Nd:YAG laser (1064 nm). Other minimally invasive or adjunctive laser approaches to periodontal and peri-implant pocket therapy using different wavelengths have been described and are distinct from LANAP. A review reports that CO2 laser systems share soft-tissue applications with diode and Nd:YAG lasers (bacterial reduction, debridement in pockets and around implants, and coagulation), but that clinical studies and meta-analyses have not consistently shown statistically significant improvements versus mechanical debridement alone. For peri-implant diseases, an AAP best-evidence review and meta-analysis reported that laser therapy in combination with surgical or non-surgical therapy provided minimal benefit for several clinical outcomes, and noted that the controlled evidence included in the analyses was limited to Er:YAG, CO2 laser, and diode lasers. In 2016, the FDA cleared labeling for an Nd:YAG system that included an indication describing “promotion of true regeneration” (new cementum, periodontal ligament, and alveolar bone) when used specifically in the LANAP protocol. A 2017 review concluded that studies of lasers in the treatment of periodontitis had not provided sufficient evidence that laser use provides benefit over traditional therapy.
== Beta-2 agonists == All beta-2 agonists and their D- and L-isomers, are banned. However, formoterol, salbutamol, salmeterol, and terbutaline may be used with a "therapeutic use exemption", only in the inhaled form.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.
No. The two peptides share part of a name but differ in length, sequence, and net charge. Literature searches that treat them as one compound return misleading results.
Solid-phase peptide synthesis is the usual route, and recombinant expression has also been described. Both approaches produce material matching the natural sequence.